Michael Weller
迈克尔·韦勒
MD
Professor and Chairman, Department of Neurology神经内科主任、教授
👥Biography 个人简介
Michael Weller is Europe's foremost GBM researcher, leading the European Organisation for Research and Treatment of Cancer Brain Tumor Group. His work on MGMT promoter methylation as a predictive biomarker transformed GBM treatment stratification worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
MGMT Methylation Biomarker
Defined MGMT promoter methylation as a predictive biomarker for temozolomide benefit in GBM, informing treatment decisions globally.
EORTC Brain Tumor Group
Led the EORTC Brain Tumor Group, coordinating major European GBM trials and unifying research standards across continents.
Temozolomide Resistance
Elucidated molecular mechanisms of temozolomide resistance in GBM, identifying pathways for overcoming chemotherapy failure.
Representative Works 代表性著作
MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide in newly diagnosed glioblastoma
Clinical Cancer Research (2013)
Validated MGMT methylation as the key predictive marker for chemotherapy response in GBM.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly
Lancet Oncology (2012)
Established temozolomide monotherapy as preferred option for elderly GBM patients with MGMT-methylated tumors.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Timothy Cloughesy
UCLA Health / David Geffen School of Medicine
Patrick Y. Wen
Dana-Farber Cancer Institute / Harvard Medical School
Susan M. Chang
University of California San Francisco (UCSF)
Roger Stupp
Northwestern University Feinberg School of Medicine
关注 迈克尔·韦勒 的研究动态
Follow Michael Weller's research updates
留下邮箱，当我们发布与 Michael Weller（University Hospital Zurich / University of Zurich）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment